Apellis Pharmaceuticals Inc’s recently made public that its Director Dunlop A. Sinclair unloaded Company’s shares for reported $1.34 million on Sep 16 ’24. In the deal valued at $36.23 per share,37,000 shares were sold. As a result of this transaction, Dunlop A. Sinclair now holds 100,000 shares worth roughly $3.46 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Chopas James George sold 192 shares, generating $6,952 in total proceeds. Upon selling the shares at $36.21, the VP/Chief Accounting Officer now owns 38,141 shares.
Before that, Chopas James George bought 192 shares. Apellis Pharmaceuticals Inc shares valued at $6,952 were divested by the Officer at a price of $36.21 per share.
Morgan Stanley initiated its Apellis Pharmaceuticals Inc [APLS] rating to an Equal-weight in a research note published on November 21, 2024; the price target was $31. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who began to cover the stock in late October with a ‘”a Sector perform”‘ rating. William Blair began covering APLS with “an Outperform” recommendation on October 16, 2024. Scotiabank started covering the stock on October 16, 2024. It rated APLS as “a Sector outperform”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -1.09% to $34.64. Over the last five days, the stock has gained 0.03%. Apellis Pharmaceuticals Inc shares have fallen nearly -42.13% since the year began. Nevertheless, the stocks have fallen -44.78% over the past one year. While a 52-week high of $73.80 was reached on 01/09/24, a 52-week low of $24.34 was recorded on 11/05/24. SMA at 50 days reached $29.20, while 200 days put it at $40.29.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 34.12, which if violated will result in even more drops to 33.60. On the upside, there is a resistance level at 35.25. A further resistance level may holdings at 35.87. The Relative Strength Index (RSI) on the 14-day chart is 63.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.57, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 11.87%. Stochastics %K at 86.52% indicates the stock is a selling.
How much short interest is there in Apellis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Apellis Pharmaceuticals Inc stocks on 2024-11-29, growing by 1.03 million shares to a total of 21.81 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-31 was 20.79 million shares. There was a rise of 4.7%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 31, 2024 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $46 price target.
